Anthony is a Managing Partner of Alacrita and also a Venture Partner with biopharma VC SBI-JI. He specializes in strategy and due diligence.
Prior to co-founding Alacrita, Anthony was CEO of Onyvax, an immune-oncology company he co-founded, raising finance from blue chip life science investors including 3i and S.R. One.
Before Onyvax, he worked as a management consultant at Arthur D Little (where he was appointed a European Director and led the London-based pharmaceutical practice) and at The Wilkerson Group in London where he consulted to big pharma, diagnostics companies and biotech, and also produced expert reports for IPOs.
Anthony holds a PhD in Biochemistry from the University of Cambridge. He is a Fellow of the Royal Society of Biology.
Recent projects he has conducted or directed include:
CAR-T company foundation (Leucid Bio Ltd)